Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Vertex's Bold Move | Explore Vertex's $4.9 billion acquisition of Alpine Immune Sciences, offering a 67% premium and reshaping the autoimmune disease treatment landscape |
Povetacicept Promise | Delve into Alpine's lead candidate povetacicept, its potential best-in-class profile for IgAN, and its expansion into other autoimmune indications |
Pipeline Progress | Learn about Alpine's upcoming clinical milestones, including the RAINIER Phase III trial and DENALI Phase II study, set to commence in late 2024 |
Market Valuation | Analysts set a $65 price target, reflecting the acquisition price and strong confidence in Alpine's pipeline and future potential in autoimmune therapies |